Mesoblast's Back Pain Breakthrough.
Mesoblast completes pivotal back pain trial, moving closer to potential blockbuster drug.
Key Points
Opioid usage reductions lasting up to three years were observed in Mesoblast's prior MSB-DR003 trial, which informs expectations for durable opioid-sparing benefits in the DR004 study.
The DR004 trial’s primary endpoint aims to confirm durable pain reduction at 12 months, consistent with the earlier MSB-DR003 results.
Commercial upside is highlighted by a potential peak year revenue exceeding US$10 billion for Mesoblast with only single-digit market penetration.
The trial targets chronic low back pain due to degenerative disc disease in patients with less than five years’ duration, defining a specific early-onset CLBP population.
Mesoblast has finished treating all patients in its pivotal Phase 3 back-pain trial, setting up a critical readout that could make or break the company's biggest drug bet. The MSB-DR004 trial enrolled 350 patients — 50 more than originally planned — testing an intra-discal injection of rexlemestrocel-L against a sham procedure for chronic low back pain, according to Kalkine Media.
CEO Silviu Itescu called the milestone "a major step" toward what he sees as a potential blockbuster product. Top-line results are expected by mid-2027. The drug targets a condition affecting more than 7 million Americans, with analysts projecting peak annual revenue above US$10 billion at even single-digit market penetration, per Fin News Network.
What the Trial Is Testing and Why It Matters
The MSB-DR004 study is a randomized, placebo-controlled Phase 3 trial. Patients receive either a single intra-discal injection of rexlemestrocel-L or a sham procedure. The primary goal is durable pain reduction at 12 months. Secondary goals include improved physical function and reduced opioid use, according to Kalkine Media.
The trial focuses on a specific patient group: people with chronic low back pain caused by degenerative disc disease lasting less than five years. That narrow definition helps isolate patients most likely to benefit. Enrollment grew beyond the original 300-patient target, driven by strong demand from trial investigators, TipRanks reported.
Earlier Trial Showed Opioid Use Dropped for Three Years
Mesoblast's earlier MSB-DR003 trial gave the company reason for confidence. That study showed opioid use reductions lasting up to three years in patients treated with rexlemestrocel-L. Those results directly shaped the design of the DR004 trial and raised expectations for long-lasting benefits, according to Fin News Network.
Reducing opioid dependence is a major secondary goal for the DR004 trial. Chronic low back pain is one of the leading drivers of opioid prescriptions in the United States. A treatment that cuts long-term opioid use could carry significant value beyond pain relief alone, ShareCafe noted.
FDA's RMAT Tag Gives Mesoblast a Fast-Track Edge
Rexlemestrocel-L holds FDA Regenerative Medicine Advanced Therapy, or RMAT, designation. That label makes the drug eligible for priority review once Mesoblast files a Biologics License Application, or BLA. Priority review can cut the standard FDA review period roughly in half, according to Investing.com.
RMAT status also opens the door to more frequent FDA meetings during development. That kind of early regulatory dialogue can help companies avoid costly missteps before filing. For Mesoblast, the designation adds a meaningful speed advantage on the road to potential approval, TipRanks reported.
Mid-2027 Readout Sets Up a Defining Moment for Mesoblast
With treatment now complete, the 12-month follow-up clock is running. Top-line results are expected around mid-2027. That readout will determine whether Mesoblast can file for FDA approval and move toward commercializing its first major product, according to ShareCafe.
The commercial stakes are high. More than 7 million Americans suffer from chronic low back pain linked to degenerative disc disease. Even capturing a small share of that market could push annual revenues past US$10 billion at peak, Fin News Network reported. The mid-2027 data drop will be the company's defining near-term catalyst.
Sentiment
Mostly PositivePublishers
11
Articles
38
Reach
49
